Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Guggenheim Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Wed Mar 11, 6:26AM CDT

Guggenheim analyst reiterated a Buy rating on Sarepta Therapeutics yesterday and set a price target of $19.00. The company’s shares closed yesterday at $17.64.

Claim 70% Off TipRanks Premium

In addition to Guggenheim, Sarepta Therapeutics also received a Buy from Wedbush’s Yun Zhong in a report issued on March 2. However, today, Citi maintained a Sell rating on Sarepta Therapeutics (NASDAQ: SRPT).

See Insiders’ Hot Stocks on TipRanks >>

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $442.93 million and a GAAP net loss of $412.23 million. In comparison, last year the company earned a revenue of $658.41 million and had a net profit of $159.05 million

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Most recently, in December 2025, Ian Michael Estepan, the COO of SRPT sold 13,187.00 shares for a total of $294,201.97.

Read More on SRPT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).